Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers.
暂无分享,去创建一个
Makoto Yamagishi | Seishi Ogawa | Kazunari Yamaguchi | S. Ogawa | K. Nakano | K. Yamaguchi | A. Sato-Otsubo | A. Utsunomiya | K. Uchimaru | Toshiki Watanabe | A. Tsutsumi | T. Yamochi | Tadanori Yamochi | Toshiki Watanabe | Ariko Miyake | Kaoru Uchimaru | A. Miyake | Kazumi Nakano | Atae Utsunomiya | Yuka Matsuda | Aiko Sato-Otsubo | Akihisa Tsutsumi | Yayoi Kagami | Satsuki Muto | Y. Kagami | Makoto Yamagishi | Yuka Matsuda | Satsuki Muto
[1] P. Ramakrishnan,et al. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. , 2004, Immunity.
[2] G. Cheng,et al. Control of canonical NF-κB activation through the NIK–IKK complex pathway , 2008, Proceedings of the National Academy of Sciences.
[3] Toshiki Watanabe,et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. , 2004, Cancer cell.
[4] O. Hermine,et al. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. , 2009, Blood.
[5] Huidong Shi,et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.
[6] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[7] Rameen Beroukhim,et al. An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.
[8] Debashis Ghosh,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] S. Ogawa,et al. Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.
[10] K. Yamaguchi,et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. , 2005, Blood.
[11] T. Mak,et al. Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK , 2008, Nature Immunology.
[12] E. Harhaj,et al. Regulation of the NF-κB-inducing Kinase by Tumor Necrosis Factor Receptor-associated Factor 3-induced Degradation* , 2004, Journal of Biological Chemistry.
[13] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[14] K. Jeang,et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. , 2008, Cancer research.
[15] D. Wallach,et al. MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1 , 1997, Nature.
[16] D. Cooper,et al. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. , 2009, Microbes and infection.
[17] Robert A. Weinberg,et al. A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .
[18] P. Ramakrishnan,et al. Receptor-Specific Signaling for Both the Alternative and the Canonical NF-κB Activation Pathways by NF-κB-Inducing Kinase , 2004 .
[19] Anke Sparmann,et al. Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.
[20] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[21] J. Inazawa,et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. , 2008, Blood.
[22] B. Chait,et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement , 2003, Nature Immunology.
[23] K. Yamaguchi,et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. , 2010, Blood.
[24] Christoph Wülfing,et al. Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.
[25] Robert E. Kingston,et al. Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.
[26] M. Rosenfeld,et al. The RNA-binding Protein KSRP Promotes the Biogenesis of a Subset of miRNAs , 2016 .
[27] G. Kristiansen,et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.
[28] K. Yamaguchi,et al. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan , 2002, International journal of hematology.
[29] A. Rabson,et al. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? , 2004, Journal of cellular biochemistry.
[30] Andrea Ventura,et al. MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.
[31] S. Ghosh,et al. Shared Principles in NF-κB Signaling , 2008, Cell.
[32] A. Rabson,et al. NF‐κB activation in human prostate cancer: Important mediator or epiphenomenon? , 2004 .
[33] N. Mori,et al. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. , 2004, Neoplasia.
[34] J. Pollack,et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.
[35] G. Lyons,et al. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. , 2004, Genes & development.
[36] B. Aggarwal,et al. NF-κB and cancer: how intimate is this relationship , 2010, Molecular and Cellular Biochemistry.
[37] L. Staudt,et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.
[38] A. Richmond,et al. NF-κB inducing kinase: a key regulator in the immune system and in cancer. , 2010, Cytokine & growth factor reviews.
[39] A. Hata,et al. SMAD proteins control DROSHA-mediated microRNA maturation , 2008, Nature.